المؤلفون: M. Yu. Fedyanin, L. Yu. Vladimirova, V. A. Chubenko, L. A. Zagorskaya, A. V. Belyaeva, O. L. Fakhrutdinova, S. A. Belukhin, A. S. Zhabina, L. V. Khalikova, L. V. Bolotina, R. V. Orlova, F. V. Moiseenko, G. Z. Mukhametshina, A. I. Khasanova, A. V. Belonogov, Kh. S. Musaeva, O. Yu. Novikova, I. Yu. Stradaeva, I. L. Popova, S. P. Erdniev, A. K. Ivanova, A. V. Androsova, P. S. Feoktistova, E. S. Kuzmina, E. V. Karabina, O. V. Nekrasova, O. V. Sekhina, A. A. Mishchenko, L. A. Mukova, B. Kh. Kertiev, G. I. Kosar, S. N. Osodoeva, A. I. Kats, R. R. Malina, M. A. Lyadova, A. A. Tryakin, S. A. Tyulandin

المصدر: Тазовая хирургия и онкология, Vol 11, Iss 3-4, Pp 11-17 (2022)

مصطلحات موضوعية: colon cancer, chemotherapy, aflibercept, bevacizumab, population-based study, Neoplasms. Tumors. Oncology. Including cancer and carcinogens, RC254-282

وصف الملف: electronic resource

العلاقة: https://ok.abvpress.ru/jour/article/view/518Test; https://doaj.org/toc/2686-9594Test

الوصول الحر: https://doaj.org/article/2d03f1018a45430f833cbda769ac5776Test

المؤلفون: M. Yu. Fedyanin, L. Yu. Vladimirova, V. A. Chubenko, L. A. Zagorskaya, A. V. Belyaeva, L. V. Bolotina, F. V. Moiseenko, O. L. Fakhrutdinova, S. A. Belukhin, A. S. Zhabina, L. V. Khalikova, V. M. Moiseenko, А. А. Meshcheryakov, E. V. Artamonova, I. A. Pokataev, A. I. Khasanova, A. V. Belonogov, Kh. S. Musaeva, O. Yu. Novikova, I. Yu. Stradaeva, I. L. Popova, G. Z. Mukhametshina, R. V. Orlova, S. P. Erdniev, A. K. Ivanova, A. V. Androsova, P. S. Feoktistova, E. S. Kuzmina, E. V. Karabina, O. V. Nekrasova, V. M. Sherstnev, A. A. Mishchenko, L. A. Mukova, B. Kh. Kertiev, G. I. Kosar, S. N. Osodoeva, A. I. Kats, R. R. Malina, A. A. Tryakin, S. A. Tjulandin

المصدر: Тазовая хирургия и онкология, Vol 9, Iss 2, Pp 29-37 (2019)

مصطلحات موضوعية: colon cancer, chemotherapy, aflibercept, population-based study, prognostic factors, Neoplasms. Tumors. Oncology. Including cancer and carcinogens, RC254-282

وصف الملف: electronic resource

العلاقة: https://ok.abvpress.ru/jour/article/view/289Test; https://doaj.org/toc/2686-9594Test

الوصول الحر: https://doaj.org/article/743bdd161bd0481991ada713bfba7dbcTest

المؤلفون: M. Yu. Fedyanin, L. Yu. Vladimirova, V. A. Chubenko, L. A. Zagorskaya, A. V. Belyayeva, L. V. Bolotina, F. V. Moiseyenko, O. L. Fakhrutdinova, S. A. Belukhin, A. S. Zhabina, L. V. Khalikova, V. M. Moiseyenko, A. A. Meshcheryakov, E. V. Artamonova, I. A. Pokatayev, A. I. Khasanova, A. V. Belonogov, Kh. S. Musayeva, O. Yu. Novikova, I. Yu. Stradayeva, I. L. Popova, G. Z. Mukhametshina, R. V. Orlova, S. P. Erdniev, A. K. Ivanova, A. V. Androsova, P. S. Feoktistova, Ye. S. Kuzmina, Ye. V. Karabina, O. V. Nekrasova, V. M. Sherstnev, A. A. Mishchenko, L. A. Mukova, B. Kh. Kertiev, G. I. Kosar, S. N. Osodoyeva, A. I. Katz, R. R. Malina, A. A. Tryakin, S. A. Tyulyandin, М. Ю. Федянин, Л. Ю. Владимирова, В. А. Чубенко, Л. А. Загорская, А. В. Беляева, Л. В. Болотина, Ф. В. Моисеенко, О. Л. Фахрутдинова, С. А. Белухин, А. С. Жабина, Л. В. Халикова, В. М. Моисеенко, А. А. Мещеряков, Е. В. Артамонова, И. А. Покатаев, А. И. Хасанова, А. В. Белоногов, Х. С. Мусаева, О. Ю. Новикова, И. Ю. Страдаева, И. Л. Попова, Г. З. Мухаметшина, Р. В. Орлова, С. П. Эрдниев, А. К. Иванова, А. В. Андросова, П. С. Феоктистова, Е. С. Кузьмина, Е. С. Карабина, О. В. Некрасова, В. М. Шерстнев, А. А. Мищенко, Л. А. Мукова, Б. Х. Кертиев, Г. И. Косарь, С. Н. Осодоева, А. И. Кац, Р. Р. Малина, А. А. Трякин, С. А. Тюляндин

المصدر: Malignant tumours; Том 9, № 2 (2019); 53-63 ; Злокачественные опухоли; Том 9, № 2 (2019); 53-63 ; 2587-6813 ; 2224-5057

مصطلحات موضوعية: популяционное исследование, chemotherapy, aflibercept, population study. Colorectal cancer, population study, химиотерапия, афлиберцепт

وصف الملف: application/pdf

العلاقة: https://www.malignanttumors.org/jour/article/view/629/441Test; Van Cutsem E, Tabernero J, Lakomy R, et al. Addition of aflibercept to fluorouracil, leucovorin, and irinotecan improves survival in a phase III randomized trial in patients with metastatic colorectal cancer previously treated with an oxaliplatin-based regimen. J Clin Oncol. 2012 Oct 1;30 (28):3499-506.; Riechelmann R, Srimuninnimit V, Kavan P. Aflibercept plus FOLFIRI for 2nd line treatment of metastatic colorectal cancer (mCRC): Long-term safety observation from the global aflibercept safety and quality-of-life (QoL) program (ASQoP). Annals of Oncology (2016) 27 (6): 149-206.; Pastorino A, Di Bartolomeo M, Maiello E, et al. Aflibercept Plus FOLFIRI in the Real-life Setting: Safety and Quality of Life Data From the Italian Patient Cohort of the Aflibercept Safety and Quality-of-Life Program Study. Clin Colorectal Cancer. 2018 Sep;17 (3):e457-e470.; Montes AF, Lago NM, Rua MC, et al. Efficacy and safety of FOLFIRI/ aflibercept in second-line treatment of metastatic colorectal cancer in a real-world population: Prognostic and predictive markers. Cancer Medicine. 2018;1-8.; Hofheinz R, Thaler J, Von Moos R, et al. Quality of life (QoL) and therapy management in metastatic colorectal cancer (mCRC) patients treated with FOLFIRI and aflibercept in Germany, Switzerland, and Austria (GSA): Interim results of the noninterventional QoLiTrap-study. Journal of Clinical Oncology 34, no. 4_suppl (February 12016) 681-681.; Hofheinz RD, Derigs H, Piringer G, et al. Interim analysis of the non-interventional study QoLiTrap (AIO-LQ-0113) in patients with metastatic colorectal cancer (mCRC) treated with aflibercept (AFL) + FOLFIRI: Efficacy according to age group 65 years. Annals of Oncology. 2018;29 (suppl_8).; Ivanova JI, Saverno KR, Sung J, et al. Real-world treatment patterns and effectiveness among patients with metastatic colorectal cancer treated with ziv-aflibercept in community oncology practices in the USA. Med Oncol. 2017 Nov 4;34 (12):193.; Pentheroudakis G, Kotoula V, Koliou GA, et al. AMALTHEA: Prospective, Single-Arm Study of the Hellenic Cooperative Oncology Group (HeCOG) Evaluating Efficacy and Safety of First-Line FOLFIRI + Aflibercept for 6 Months Followed by Aflibercept Maintenance in Patients With Metastatic Colorectal Cancer. Clin Colorectal Cancer. 2018 Dec;17 (4):e631-e637.; Carola C, Ghiringhelli F, Kim S, et al. FOLFIRI3-aflibercept in previously treated patients with metastatic colorectal cancer. World J Clin Oncol. 2018 Sep 14; 9 (5): 110-118.; https://www.malignanttumors.org/jour/article/view/629Test

الإتاحة: https://www.malignanttumors.org/jour/article/view/629Test